TGF-β1 reverses inhibition of COX-2 with NS398 and increases invasion in prostate cancer cells

American Journal of the Medical Sciences

Volumn 339, Issue 5, 2010, Pages 425-432

  Ding, Qiang ^a   Bai, Yu Feng ^a   Wang, Yong Quan ^a   An, Rui Hua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Growth factors; Inhibitor; Prostaglandin E2; Prostate cancer

Indexed keywords

CYCLOOXYGENASE 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; TRANSFORMING GROWTH FACTOR BETA1; CYCLOOXYGENASE 2 INHIBITOR; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; PROSTAGLANDIN E2; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; MALE; METABOLISM; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; NEOPLASM INVASIVENESS; NITROBENZENES; PROSTATE; PROSTATIC NEOPLASMS; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77952283358     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181d7c9db     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
3. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
4. Yang J, Fizazi K, Peleg S, et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 2001;61:5652-9.
5. Dorkin TJ, Neal DE. Basic science aspects of prostate cancer. Semin Cancer Biol 1997;8:21-7.
6. Sung SY, Chung LW. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002;70:506-21.
7. Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 2003; 97 (3 suppl) : 772-8.
8. Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002;277:24571-8.
9. Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
10. Canete JD, Llena J, Collado A, et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 1997;36:38-42.
11. Barsky SH, Siegal GP, Jannotta F, Liotta LA. Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 1983;49:140-7.
12. Iwamoto Y, Sugioka Y. Use of a reconstituted basement membrane to study the invasiveness of tumor cells. Adv Exp Med Biol 1992;324:141-9.
13. Attiga FA, Fernandez PM, Weeraratna AT, et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000;60:4629-37.
14. Angelucci A, Garofalo S, Speca S, et al. Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells. Endocr Relat Cancer 2008;15:91-100.
15. Honn KV, Nelson KK, Renaud C, et al. Fatty acid modulation of tumor cell adhesion to microvessel endothelium and experimental metastasis. Prostaglandins 1992;44:413-29.
16. Piomelli D. Arachidonic acid in cell signaling. Curr Opin Cell Biol 1993;5:274-80.
17. Chaudry A, McClinton S, Moffat LE, et al. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 1991;64:1157-60.
18. Nithipatikom K, Isbell MA, Lindholm PF, et al. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis 2002;19:593-601.
19. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
20. Aparicio Gallego G, Diaz Prado S, Jimenez Fonseca P, et al. Cyclooxygenase-2 (COX-2) : a molecular target in prostate cancer. Clin Transl Oncol 2007;9:694-702.
21. Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995;1258:215-23.
22. Sheng H, Shao J, Washington MK, et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-81.
23. Yang X, Hou F, Taylor L, et al. Characterization of human cyclooxygenase 2 gene promoter localization of a TGF-beta response element. Biochim Biophys Acta 1997;1350:287-92.
24. Shao J, Sheng H, Aramandla R, et al. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999;20:185-91.
25. Elder DJ, Halton DE, Playle LC, et al. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002;99:323-7.
26. Johnson AJ, Song X, Hsu A, et al. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 2001;41:221-35.
27. Gamradt SC, Feeley BT, Liu NQ, et al. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Anticancer Res 2005;25:107-15.
28. Morton DM, Barrack ER. Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 1995;55:2596-602.
29. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75:1111-8.
30. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511-5.
31. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97:1037-41.
32. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21.
33. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-8.
34. Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001;31:325-48.
35. Fong CY, Pang L, Holland E, et al. TGF-beta1 stimulates IL-8 release, COX-2 expression, and PGE release in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000; 279: L201-7.
36. Navone NM, Logothetis CJ, von Eschenbach AC, et al. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 1998;17:361-71.
37. Royai R, Lange PH, Vessella R. Preclinical models of prostate cancer. Semin Oncol 1996; 23 (6 suppl 14) : 35-40.